The peptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are implicated in the modulation of emotional states. Previous human and rodent findings support NOP antagonists as antidepressants. However, the role played by the N/OFQ–NOP receptor system in resilience to stress is unclear.
Aims:
The present study investigated the effects of activation or blockade of NOP receptor signaling before exposure to acute stress.
Methods:
The behavioral effects of the administration before stress of the NOP agonists Ro 65-6570 (0.01–1 mg/kg) and MCOPPB (0.1–10 mg/kg), and the NOP antagonist SB-612111 (1–10 mg/kg) were assessed in mice exposed to inescapable electric footshock and forced swim as stressors. The behavioral phenotype of mice lacking the NOP receptor (NOP(-/-)) exposed to inescapable electric footshock was also investigated.
Results:
The activation of NOP receptor signaling with the agonists increased the percentage of mice developing helpless behavior and facilitated immobile posture. In contrast, the blockade of NOP receptor reduced the acquisition of depressive-like phenotypes, and similar resistance to develop helpless behaviors was observed in NOP(-/-) mice. Under the same stressful conditions, the antidepressant nortriptyline (20 mg/kg) did not change the acquisition of helpless behavior and immobile posture.
Conclusions:
These findings support the view that NOP activation during acute stress facilitates the development of depressive-related behaviors, whereas NOP blockade has a protective outcome. This study showed for first time that NOP antagonists are worthy of investigation as preemptive treatments in patients with severe risk factors for depression.
BertorelliRBastiaECitterioF, et al. (2002) Lack of the nociceptin receptor does not affect acute or chronic nociception in mice. Peptides23: 1589–1596.
5.
BoomAMollereauCMeunierJC, et al. (1999) Distribution of the nociceptin and nocistatin precursor transcript in the mouse central nervous system. Neuroscience91: 991–1007.
6.
BorsoiMAntonioCBVianaAF, et al. (2015) Immobility behavior during the forced swim test correlates with BNDF levels in the frontal cortex, but not with cognitive impairments. Physiol Behav140: 79–88.
7.
CiccocioppoRBorrutoAMDomiA, et al. (2019) NOP-related mechanisms in substance use disorders. In: Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer. DOI: 10.1007/164_2019_209. (in press).
8.
CiccocioppoRde GuglielmoGHanssonAC, et al. (2014) Restraint stress alters nociceptin/orphanin FQ and CRF systems in the rat central amygdala: Significance for anxiety-like behaviors. Neurosci J34: 363–372.
9.
de KloetERDe KockSSchildV, et al. (1988) Antiglucocorticoid RU 38346 attenuates retention of a behavior and disinhibits the hypothalamic–pituitary–adrenal axis at different brain sites. Neuroendocrinology47: 109–115.
10.
DelaneyGDaweKLHoganR, et al. (2012) Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats. J Neuroendocrinol24: 1527–1541.
11.
Der-AvakianAD’SouzaMSPotterDN, et al. (2017) Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats. Psychopharmacology (Berl)234: 1603–1614.
12.
DevineDPHoverstenMTUedaY, et al. (2003) Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress. J Neuroendocrinol15: 69–74.
13.
DevineDPWatsonSJAkilH (2001) Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic–hypothalamic–pituitary–adrenal axis. Neuroscience102: 541–553.
14.
Di GiannuarioARizziAPierettiS, et al. (2001) Studies on the antinociceptive effect of [Nphe1]nociceptin(1–13)NH2 in mice. Neurosci Lett316: 25–28.
15.
FerrariFMalfaciniDJourniganBV, et al. (2017) In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. Pharmacol Res Perspect5.
GavioliECHolandaVADRuzzaC (2018) NOP ligands for the treatment of anxiety and mood disorders. In: Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer. DOI: 10.1007/164_2018_188. (in press).
18.
GavioliECMarzolaGGuerriniR, et al. (2003) Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: Pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci17: 1987–1990.
19.
GavioliECRaeGACalo’G, et al. (2002) Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol136: 764–772.
20.
GavioliECVaughanCWMarzolaG, et al. (2004) Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice. Naunyn-Schmiedeberg’s Arch Pharmacol369: 547–553.
21.
Gómez-CoronadoNSethiRBortolasciCC, et al. (2018) A review of the neurobiological underpinning of comorbid substance use and mood disorders. J Affect Disord241: 388–401.
22.
GranholmLRomanENylanderI (2015) Single housing during early adolescence causes time-, area- and peptide-specific alterations in endogenous opioids of rat brain. Br J Pharmacol172: 606–614.
23.
GreenMKBarbieriEVBrownBD, et al. (2009a) Roles of the bed nucleus of stria terminalis and of the amygdala in N/OFQ-mediated anxiety and HPA axis activation. Neuropeptides41: 399–410.
24.
GreenMKDevineDP (2009b) Nociceptin/orphanin FQ and NOP receptor gene regulation after acute or repeated social defeat stress. Neuropeptides43: 507–514.
25.
HiraoAImaiASugieY, et al. (2008) Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. J Pharmacol Sci106: 361–368.
26.
HolandaVAMedeirosIUAsthL, et al. (2016) Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. Psychopharmacology233: 2525–2532.
27.
HolandaVADSantosWBAsthL, et al. (2018) NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. Psychopharmacology235: 3093–3102.
28.
KallupiMScuppaGde GuglielmoG, et al. (2017) Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction. Neuropsychopharmacology42: 695–706.
29.
KilkennyCBrowneWCuthillIC, et al (2010) NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol160: 1577–1579.
30.
KösterAMontkowskiASchulzS, et al. (1999) Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci U S A96: 10444–10449.
31.
KuzminAMadjidNJohanssonB, et al. (2009) The nociceptin system and hippocampal cognition in mice: A pharmacological and genetic analysis. Brain Res1305(Suppl): S7–S19.
32.
LeggettJDHarbuzMSJessopDS, et al. (2006) The nociceptin receptor antagonist [Nphe1, Arg14, Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats. Neuroscience141: 2051–2057.
33.
MartiMMelaFVeronesiC, et al. (2004) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci24: 6659–6666.
34.
MedeirosIURuzzaCAsthL, et al. (2015) Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice. Peptides72: 95–103.
35.
MeunierJCMollereauCTollL, et al. (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature377: 532–535.
36.
MillerLRMarksCBeckerJB, et al. (2017) Considering sex as a biological variable in preclinical research. FASEB J31: 29–34.
37.
MollereauCMouledousL (2000) Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides21: 907–917.
38.
MoulédousL (2019) The nociceptin/orphanin FQ system and the regulation of memory. In: Handbook of Experimental Pharmacology254: 259–278.
39.
NagaiJKurokawaMTakeshimaH, et al (2007) Circadian-dependent learning and memory enhancement in nociceptin receptor-deficient mice with a novel KUROBOX apparatus using stress-free positive cue task. J Pharmacol Exp Ther321: 195–201.
40.
NarendranRTollefsonSFasenmyerK, et al. (2019) Decreased nociceptin receptors are related to resilience and recovery in college women who have experienced sexual violence: Therapeutic implications for posttraumatic stress disorder. Biol Psychiatry. DOI: 10.1016/j.biopsych.2019.02.017.
41.
NativioPPascaleEMaffeiA, et al. (2012) Effect of stress on hippocampal nociceptin expression in rat. Stress15: 378–384.
42.
NealCRMansourAReinscheidR, et al. (1999a) Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol406: 503–547.
43.
NealCRMansourAReinscheidR, et al. (1999b) Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: Comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol412: 563–605.
44.
NishiMHoutaniTNodaY, et al. (1997) Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J16: 1858–1864.
45.
PfauMLRussoSJ (2015) Peripheral and central mechanisms of stress resilience. Neurobiol Stress1: 66–79.
46.
PostASmartTSKrikke-WorkelJ, et al. (2016) A selective nociceptin receptor antagonist to treat depression: Evidence from preclinical and clinical studies. Neuropsychopharmacology41: 1803–1812.
47.
RedrobeJPCalo’GRegoliD, et al. (2002) Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol365: 164–167.
48.
ReinscheidRKNothackerHPBoursonA, et al. (1995) Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science270: 792–794.
49.
ReissDWolter-SutterAKrezelW, et al. (2007) Effects of social crowding on emotionality and expression of hippocampal nociceptin/orphanin FQ system transcripts in mice. Behav Brain Res184: 167–173.
50.
RizziACerlesiMCRuzzaC, et al. (2016) Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacol Res Perspect4: e00247.
51.
RizziAGavioliECMarzolaG, et al. (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6- dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies. J Pharmacol Exp Ther321: 968–974.
52.
RizziAMolinariSMartiM, et al. (2011) Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies. Neuropharmacology60: 572–579.
53.
SilvaEFSilvaAIAsthL, et al. (2018) Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test. Behav Brain Res356: 120–126.
54.
SpagnoloBCarràGFantinM, et al. (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther321: 961–967.
55.
TakamoriKKawashimaNChakiS, et al. (2001) Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats. Life Sci69: 1241–1248.
56.
ToledoMAPedregalCLafuenteC, et al. (2014) Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7’-thieno[2,3-c]pyran) scaffold. J Med Chem57: 3418–3429.
57.
TollLBruchasMRCalo’G, et al. (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev68: 419–457.
58.
VitaleGFilaferroMMicioniDiBonaventuraMV, et al. (2017) Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. J Psychopharmacol31: 691–703.
59.
VitaleGRuggieriVFilaferroM, et al. (2009) Chronic treatmentwith the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology (Berl)207: 173–189.
60.
VollmayrBGassP (2013) Learned helplessness: Unique features and translational value of a cognitive depression model. Cell Tissue Res354: 171–178.
61.
WellmanCLBangasserDABollingerJL, et al. (2018) Sex differences in risk and resilience: Stress effects on the neural substrates of emotion and motivation. J Neurosci38: 9423–9432.
62.
WichmannJAdamGRöverS, et al. (1999) 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg Med Chem Lett9: 2343–2348.
63.
WitkinJM.Rorick-KehnLMBenvengaMJ, et al. (2016) Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect4: e00275.
64.
XieGXItoEMaruyamaK, et al. (1999) The promoter region of human prepro-nociceptin gene and its regulation by cyclic AMP and steroid hormones. Gene238: 427–436.
65.
ZaratinPFPetroneGSbacchiM, et al. (2004) Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther308: 454–461.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
